OBI is eligible to receive up to US$ 200 million in total milestone payments and tiered double-digit royalties on net sales. TAIPEI, Taiwan, Feb. 22, 2022 /PRNewswire/ OBI Pharma, Inc.
/PRNewswire/ OBI Pharma, Inc. (OBI), a Taiwan biopharma company (TPEx: 4174), and Odeon Therapeutics (Odeon), a China biopharma company, have entered into.
/PRNewswire/ OBI Pharma, Inc. (OBI), a Taiwan biopharma company (TPEx: 4174), and Odeon Therapeutics (Odeon), a China biopharma company, have entered into.
/PRNewswire/ OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced that the first patients have been enrolled in both of the Phase 2 studies.